Healthcare Professional

Metoject® 10mg/ml


Metoject 15mg Syringe

Metoject® Subcutaneous 50mg/ml


Metoject 15mg Syringe
  • Methotrexate (MTX) remains the anchor drug among DMARDs1, 2, 3, 4
  • Parenteral MTX offers an earlier onset of action and increased bioavailability compared to oral MTX5, 6, 7
  • Less gastrointestinal side-effects compared to oral MTX8
  • Greater patient comfort with s.c. injection compared to i.m. injection9

ACR 20 subgroup analysis at week 24

MTX Chart
MTX Chart
MTX Chart
MTX Chart


1. Pincus T, Yazici Y, Sokka T et al., Clin Exp Rheumatol 2003; 21(Suppl 31):S179-S185
2. Visser et al., Ann Rheum Dis 2009; 68:1086-1093
3. Braun J, Rau R, Curr Opin Rheumatol 2009; 2:216-223
4. Sokka T, Clin Exp Rheumatol 2010; 61:13-20
5. Visser et al., Ann Rheum Dis 2009; 68:1094-1099
6. Roon E, Laar M, Clin Exp Rheumatol 2010; 61:27-32

7. Braun J, et al., Arthritis Rheum 2008; 58 (1):73-81
8. Rutkowska-Sak et al., Rheumatologia 2009; 47(4):207-211
9. Brooks PJ et al., Arthritis Rheum 1990; 33:91-94
10. Braun J. et al., Arthritis Rheum. 2008; 58 (1): 73-81
11. Rutkowska-Sak et al., Rheumatologia 2009; 47(4): 207-211

Metoject® Offers Injection Training to Help Your Patients


Please download the attached form and follow the instructions. You can also contact Medexus 1-877-633-3987


Download Registration and Prescription Form